Table 6.
Analysis of primary outcome of diagnosis of diabetes in Ontario Diabetes Database in new users of statins by statin potency
| Statin | No of patients | No of outcomes | No of outcomes per 1000 person years | HR (95% CI) | |
|---|---|---|---|---|---|
| Unadjusted | Adjusted* | ||||
| Pravastatin | 38 470 | 1443 | 22.64 | Reference | Reference |
| High potency (atorvastatin, rosuvastatin) | 345 028 | 18 993 | 31.34 | 1.39 (1.32 to 1.47) | 1.22 (1.15 to 1.29) |
| Moderate potency (simvastatin) | 75 829 | 3727 | 26.22 | 1.17 (1.1 to 1.24) | 1.11 (1.04 to 1.18) |
| Low potency (fluvastatin, lovastatin) | 11 923 | 378 | 21.68 | 0.95 (0.85 to 1.06) | 0.97 (0.87 to 1.09) |
*Adjusted for age, sex, year of cohort entry, recent acute coronary syndrome, chronic coronary artery disease, Charlson score and previous use of diuretic (thiazide), nitroglycerin, angiotensin receptor blocker, β blocker, hormones and analogues.